---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294358643.md"
description: "60 Degrees Pharmaceuticals shares are trading higher after the company announced it enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis."
datetime: "2026-07-29T20:58:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294358643.md)
  - [en](https://longbridge.com/en/news/294358643.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294358643.md)
generator: "portal-rs"
---

# 

60 Degrees Pharmaceuticals shares are trading higher after the company announced it enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis.

### Related Stocks

- [SXTP.US](https://longbridge.com/en/quote/SXTP.US.md)
- [SXTPW.US](https://longbridge.com/en/quote/SXTPW.US.md)

## Related News & Research

- [60 Degrees Pharma hits minimum enrollment trigger for interim readout in severe babesiosis tafenoquine trial](https://longbridge.com/en/news/294254910.md)
- [60 Degrees Pharmaceuticals issues Series A, Series B warrants exercisable at $1.49 in $1 million private placement](https://longbridge.com/en/news/294876524.md)
- [Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test](https://longbridge.com/en/news/296382081.md)
- [CytoSorbents releases investor presentation on blood purification devices for ICU, cardiac surgery use](https://longbridge.com/en/news/296280537.md)
- [Akari Targets Mid-2027 for Human Trial of Differentiated Cancer Therapy](https://longbridge.com/en/news/296250397.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**